He Ying, Zhai Aili, Qin Kaiyun, Zhou Xin, Yu Yu, Zhang Zhengmao
Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Department of Gynecology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, Hebei, China.
Discov Oncol. 2024 Aug 29;15(1):383. doi: 10.1007/s12672-024-01267-8.
The current research aims to evaluate the efficacy and safety of anlotinib, an orally administered small-molecular tyrosine kinase inhibitor (TKI), in the treatment of recurrent epithelial ovarian cancer (EOC).
Patients with recurrent EOC subjected to treatment with anlotinib in Fourth Hospital of Hebei Medical University from 2020 to 2022 were included. The evaluation involved a thorough review of medical records, focusing on parameters such as the objective response rate (ORR), disease control rate (DCR), survival outcomes, and safety profile.
This study recorded 51 patients, with 26 patients undergoing anlotinib monotherapy. The median progression-free survival (PFS) was 4.0 months, whereas the median overall survival (OS) was not reached. Seven cases underwent a combined treatment of anlotinib with chemotherapy. Among them, two patients achieved partial response (PR), two were categorized as stable disease (SD), and three were identified as having progressive disease (PD). The ORR and DCR were 28.5% (2/7) and 57.1% (4/7), respectively. Additionally, 18 cases received anlotinib maintenance therapy, and the median PFS and the median OS were 7.0 months and 25.5 months, respectively. The most prevalent adverse effects included fatigue (38.6%), hypertension (27.3%), nausea and vomiting (25.0%) and hand-foot syndrome (25.0%).
Anlotinib demonstrated mild efficacy in the treatment of recurrent EOC, whether employed as monotherapy, chemotherapy-combined therapy, or maintenance therapy. The safety profile was proven manageable and well-tolerated, suggesting that anlotinib may emerge as a viable and novel treatment option for recurrent EOC.
本研究旨在评估口服小分子酪氨酸激酶抑制剂（TKI）安罗替尼治疗复发性上皮性卵巢癌（EOC）的疗效和安全性。
纳入2020年至2022年在河北医科大学第四医院接受安罗替尼治疗的复发性EOC患者。评估包括对病历的全面审查，重点关注客观缓解率（ORR）、疾病控制率（DCR）、生存结果和安全性等参数。
本研究记录了51例患者，其中26例接受安罗替尼单药治疗。中位无进展生存期（PFS）为4.0个月，而中位总生存期（OS）未达到。7例患者接受了安罗替尼与化疗的联合治疗。其中，2例患者达到部分缓解（PR），2例为疾病稳定（SD），3例为疾病进展（PD）。ORR和DCR分别为28.5%（2/7）和57.1%（4/7）。此外，18例患者接受了安罗替尼维持治疗，中位PFS和中位OS分别为7.0个月和25.5个月。最常见的不良反应包括疲劳（38.6%）、高血压（27.3%）、恶心和呕吐（25.0%）以及手足综合征（25.0%）。
安罗替尼在治疗复发性EOC方面显示出轻度疗效，无论是作为单药治疗、化疗联合治疗还是维持治疗。安全性经证实易于管理且耐受性良好，表明安罗替尼可能成为复发性EOC一种可行的新型治疗选择。
